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Abstract
Objective: To appraise information resources on newborn blood spot screening 
currently available for parents and health professionals internationally.
Method: Health information on newborn blood spot screening was sourced 
internationally through the internet and, in the United Kingdom, through health 
service providers and support organisations.  An appraisal tool was developed based 
on DISCERN criteria for evaluating information about patient treatment choices and 
UK National Screening Committee criteria for determining whether a screening 
programme should be implemented.  Two researchers independently applied the 
appraisal tool to all the leaflets describing the heel prick, then discussed and resolved 
discrepancies.
Results: The majority of leaflets supported the public health agenda by 
informing parents of the benefits of screening, including the significance of early 
detection and treatment for these conditions.  Few leaflets, however, supported the 
informed choice agenda by mentioning either the limitations of screening, or choice, 
or by being easy to read.
Conclusion:  Most health information about newborn blood spot screening portrays 
it in a positive light, and relatively few leaflets address the difficulties openly.  We 
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recommend the use of criteria for high-quality patient information alongside topic or 
condition-specific guidelines as a starting point for developing patient information.
Introduction
Population screening programmes are regarded as important public health priorities 
(1;2).  However, screening programmes have their limitations in that they may 
provide false reassurance or anxiety through inaccurate results, or difficulties with 
equivocal results or results that label individuals with an inconsequential condition 
or genetic carrier status (3). The public health approach emphasises high uptake of 
screening rather than informed participation (4;5). New policies supporting realistic 
expectations and informed choice in healthcare, however, are driving the need for 
good quality research-based information for patients (6). Facilitating realistic 
expectations and/or informed choice means increasing openness about the 
difficulties and limitations as well as the benefits of screening, and providing 
understandable information for participants. 
A changing balance in policy between supporting public health priorities and 
encouraging realistic public expectations or informed choice for screening is evident 
since the National Screening Committee for England (NSC) published its first criteria 
for appraising the viability, effectiveness and appropriateness of a screening 
programme (1). The NSC’s additional criteria in the second report are included to 
assist people further in making informed choices about screening (2). Criteria added 
3
CONFIDENTIAL – NOT FOR CIRCULATION
in a more recent report of the NSC’s Director relate specifically to the identification of 
unaffected carriers of the conditions and genetic testing (7).
All such issues are now being addressed by the UK Newborn Screening Programme 
Centre, funded by the Department of Health on behalf of all UK countries since April 
2002, including the provision of information for parents of newborn babies. All 
newborns in the UK are offered screening for the serious but rare conditions of 
phenylketonuria (PKU) and congenital hypothyroidism and, in some areas, sickle 
cell disorders and/ or cystic fibrosis. This involves a heel prick to collect a series of 
bloodspots for laboratory testing. Parents are to be given evidence-based 
information, explaining the consequences of testing, investigation and treatment, as 
recommended by the National Screening Committee to assist them in making an 
informed choice about screening their baby (7). 
This paper reports the findings of an international survey of leaflets on newborn 
blood spot screening for parents and health professionals, carried out as part of the 
process of developing evidence-based information resources (8).
Methods
We sourced leaflets and information sheets through internet websites, health service 
providers, including screening laboratories, other screening programme co-
ordinators such as the NHS Sickle Cell and Thalassaemia Screening Programme (9), 
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and parent support organisations.  To match our objective of preparing pre-screening 
parent information, we included in the survey only those leaflets that described the 
process of taking the blood spots from a baby’s heel, excluding leaflets that focussed 
only on the condition identified through screening.
To judge whether leaflets contained information about the difficulties as well as the 
benefits of screening, we developed an appraisal tool.  The questions contained in the 
tool were adapted from DISCERN criteria for appraising information about patient 
treatment choices(10), and National Screening Committee criteria for determining 
whether a screening programme should be implemented (1;2;7). Two researchers 
refined the tool by applying it to a small number of leaflets until consensus was 
reached.  The finalised tool was entered into specialist software, EPPI-Reviewer (11), 
and used to evaluate each leaflet (see Box 1).
Two researchers appraised each leaflet using the finalised appraisal tool, compared 
answers, and addressed discrepancies to reach consensus on the answers to each 
question.  Using EPPI-Reviewer, we analysed how many leaflets addressed the 
positive aspects of screening (in support of the public health agenda) and how many 
also provided information about the limitations of screening, and were presented in 
a clear, accessible way (in support of informed choice). 
Results
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We found over 300 information sheets and leaflets about newborn bloodspot 
screening.  One hundred and six leaflets described the heel prick and were included 
in our analysis: 68 from the UK (64 per cent); 34 from the USA (33 per cent); and four 
from Australia (4 per cent).
We found leaflets usually described the benefits of screening, and sometimes 
described the limitations of screening and choices open to parents. They varied in 
terms of their explicit reference to evidence and their ease of reading. We describe 
this in more detail below.
Benefits of screening
Most leaflets favoured screening. The vast majority of them (88/106) explained the 
primary aim of screening: to identify babies who are at higher risk of some rare but 
serious conditions.  Some presented specific information about the rarity of these 
conditions in a particular population (24/106).  Three-quarters of the leaflets 
described the conditions for which newborns were being screened (79/106).  Over 
two-thirds mentioned the treatment available for one or more of the conditions for 
babies identified through screening (73/106). Less than half mentioned the difficulties 
of preventing the conditions (43/106) thereby increasing the need for screening; only 
39/106 explained that the conditions were inherited, and only 11/106 mentioned 
reproductive choice. 
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Generally, leaflets also portrayed a comprehensive screening service. The majority of 
leaflets described the screening process, outlining the procedures involved in 
screening: 93/106 how the blood sample is taken, and 72/106 how the sample is sent 
to the laboratory. Many of the leaflets also reassured parents that additional support 
was available for them (66/106); 48/106 referred to general practitioners, midwives or 
specialists, and 23/106 referred to support organisations within or external to the 
health service.  Sixteen leaflets referred to counselling (including genetic counselling) 
and 16/106 referred to other services such as supplementary screening programmes. 
Over two-thirds of the leaflets (71/106) indicated that follow-up tests would be 
needed to confirm the results for babies thought to be affected by the conditions, 
almost all of which indicated in what circumstances these further tests would be 
needed (69/106).
Difficulties/limitations of screening
Leaflets were less forthcoming about technical difficulties with screening, 
inconsistencies in the communication of results to parents, costs or the controversial 
issue of retaining samples for use once screening was complete. 
Few leaflets mentioned that the test would be uncomfortable for the baby (19/106) or 
how the pain might be eased (5/106), although 76 leaflets mentioned the possibility 
that a second blood sample might be required.  Only 3/106 leaflets mentioned that 
the cards on which the blood spots are collected are stored, or provide any 
information about possible uses of these stored cards.
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Fewer than half of the leaflets indicated when parents would receive results (45/106), 
and fewer than half of these mentioned both when parents might receive negative 
results (‘all clear’) and positive results (i.e. their baby may have a condition).
Only a few explained when parents would be told if there was a need for follow-up 
tests (9/71), when these tests might occur (12/71), or when the results might be 
available (1/71).
Few leaflets contained information about the limitations or possible harms of 
screening: 19/106 mentioned false-negative results (that some babies affected by the 
conditions would be ‘missed’ by screening); 22/106 mentioned false-positive results 
(that some healthy babies might be thought to be affected in error); and 41/106 
leaflets mentioned other possible harms, such as worry caused to parents (although 
these were often expressed as exhortations not to worry). 
Only 14/106 leaflets referred to both false-negative and false-positive results. Thirteen 
of these were produced in the United States:  10 for parents and 3 for professionals. 
One was created for health professionals in the UK.  Some parent information 
created by US state health departments was in connection with piloting 
supplementary screening programmes, where more information is provided on the 
risks and benefits of participating in the pilot.  For example, the New England 
Screening Programme information sheet stipulates that: 
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If your baby has an abnormal screening result, it is possible that your baby 
actually does not have the disorder.  To be sure, your baby’s doctor may 
recommend further testing by a specialist who may take additions 
specimens…. If your baby has a normal screening result, there is still a chance 
that your baby has the disorder (i.e. for some reason, the disorder was not 
detected by the newborn screen)…. This risk exists for all forms of screening 
(12).
This level of information on the risks of screening generally did not appear in leaflets 
from the UK. We found three exceptions. The first was the following health 
professional information found on the publicly available Contact a Family website:
For most tests, some people with a positive result will turn out not to have the 
disorder (‘false positive’) and some with a negative result will subsequently be 
shown to have the disorder (‘false negative’).  Those people who have a 
positive result on the screening test (‘diagnostic test’), which will pick out much 
more accurately those who have the disorder (13).
Two other UK exceptions were parent leaflets provided in Scotland and Trent that 
addressed the limitations of screening, albeit only in relation to cystic fibrosis.  The 
Scottish parent leaflet produced in 2002 states that:
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Several factors other than cystic fibrosis can affect the test result and therefore 
not all babies with a high IRT [screen positive test result] will have cystic 
fibrosis…. Also, it should be noted that on rare occasions the IRT test will fail to 
identify a baby with cystic fibrosis (14).  
The parent leaflet produced in 2001 by the Trent Region Neonatal Metabolic 
Screening Service states, “This disease [cystic fibrosis] affects roughly 1 baby in 3000 
and the majority of cases will be picked up.”  Later in the leaflet, under the heading 
“The fine details” and in smaller print, it states, “Unfortunately, whilst it is the best 
that is available, this is not a very good test.  Several factors other than cystic fibrosis 
influence the amount of immunoreactive trypsinogen in the blood [screen positive 
test result] and we have to have a second-stage to the screen”(15).
Fourteen leaflets (14/106) mentioned the costs of screening, and only 5/106 referred to 
the cost-effectiveness of screening. The majority of these were from the United States, 
where screening is often funded by health insurance companies.
Explicit about choice
Only a third of the leaflets indicated whether or not screening was mandatory 
(38/106). The other 68 mentioned nothing about choice at all.  Sixteen leaflets (all 
from the United States) said that screening was mandatory, and 25 leaflets said that 
screening was a choice (three of these were referring to a choice over supplementary 
screening where the core screening is mandatory).  Ten leaflets that said screening 
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was a choice also recommend screening to parents, whilst four stressed the negative 
implications of not screening.
Clear communication of up-to-date evidence
To facilitate realistic expectations or to inform choice, information provided should 
be clearly communicated to its target audience, at the right time and supported by 
up-to-date research evidence. The target audience for the information was clear in 
98/106 of the leaflets.  Sixty-one of the leaflets indicated when they would be relevant 
or when they should be given. Over half the leaflets indicated the date of 
development or review (56/106).  Similarly, over half (56/106) were appraised as 
‘easy to read’, although 36/106 included technical terms that were unexplained, and 
14/106 needed expert knowledge to understand.  Only 17/106 cited any sources of 
evidence for the information contained in them, referring to policy documents, 
research papers or medical specialists who had reviewed the content of the leaflet. 
Information about carriers and genetic testing
Almost half of the leaflets (49/106) referred to carriers.  About half of these (23/49) 
indicated that, as an outcome of screening, babies may be identified as carriers of 
cystic fibrosis (10), sickle cell disorders (9), PKU (2) or other disorders (3). Twelve 
leaflets mentioned that babies’ DNA might be tested, and 19 mentioned the 
implications of carrier status for babies’ health.  Almost half of the leaflets 
mentioning carriers (24/49) indicated that parents might be carriers of sickle cell 
disorders (10), PKU (9), cystic fibrosis (8) or other disorders (4). The following 
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information relating to carrier status also appeared in some of the leaflets:  the 
implications of being a carrier for family planning and reproductive choice (19); 
wider carrier testing for family members (10); uncertainty regarding diagnosis (8); 
the number of carriers in the population (8); the psychological implications (e.g. 
anxiety) (6); not all mutations are tested for (4); and the number of mutations tested 
for (3).
Discussion
Summary of findings
The majority of leaflets support the public health agenda by informing parents of the 
benefits of screening.  These included: the aims of screening; information about the 
conditions screened; benefits of early treatment for babies found to have the 
conditions; how the screening test is carried out; and information about follow-up 
tests.
Many leaflets did not facilitate realistic expectations or support the informed choice 
agenda, either failing to mention limitations, or not mentioning choice, or being 
difficult to understand.  Few leaflets mentioned alternatives to screening, how and 
when parents would receive results, or provided sources of evidence or described 
how the information was developed.
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More leaflets from the US, compared with those from the UK, provided information 
on the limitations of screening, particularly the possibility of false results, although 
these were still a minority.  Whilst there was a dearth of this type of information in 
UK leaflets, it appears that more recent leaflets are beginning to address this more 
openly.  This is in the context of screening for cystic fibrosis where there is a greater 
risk of false results than for other conditions.
Strengths and weaknesses of the study
The study involved carrying out a wide search for information resources through the 
internet, and through a selection of health service and support organisations 
throughout the UK. Our searching strategy, however, was not exhaustive. In 
developing and using the tool, two researchers performed double data extraction 
independently and compared results.  However, this is a very small-scale exercise, 
compared with the use of a large Expert Panel and network of testers in developing 
the original DISCERN instrument (10).
In developing our tool, we drew on both NSC criteria, which are topic specific and 
policy focussed, and DISCERN criteria, which are broader and more focussed on the 
patient/individual.  The researchers were generous in applying the criteria.  Some 
leaflets were judged to have met the criteria even if the information provided was 
extremely brief.
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Some contradictions were evident in categorising information as either presenting 
the benefits or difficulties/harms of screening.  For example, we have listed the 
possible need for repeat testing as a limitation of screening.  This is because repeat 
testing can cause worry for parents, and highlights some of the uncertainties of 
screening.  However, repeat testing could also be considered a benefit, in that it 
provides evidence of follow-up procedures to ensure that screening is done correctly 
and all affected babies detected. 
Nevertheless, the appraisal tool was able to distinguish parent information in terms 
of the type and style of information provided, and to indicate its reliability in terms 
of how and when it had been produced.
Relating to other surveys of patient information
Other studies that have examined and evaluated patient information about screening 
have also concluded that the risks, limitations or difficulties were not openly 
discussed.  An Australian survey evaluating 58 leaflets on screening for breast cancer 
found that the benefits of screening were reported only ever as relative risk reduction 
and never as absolute risk reduction, thereby exaggerating the benefit (16).  
Another study of 27 websites compared information on the possible benefits and 
harms of screening for breast cancer provided by different groups (17). The authors 
concluded that information provided by professional advocacy groups and 
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government organisations were biased in favour of screening.  In contrast, 
information on consumer websites was more balanced and comprehensive.
Other small qualitative studies have been carried out to evaluate existing patient 
information.  One such study of information on gastroscopy procedures in seven 
different hospitals, found that the quality of information varied between units, most 
leaflets lacked vital information, or included information that was confusing or 
ambiguous, and that information about risks was included in only one leaflet (18). 
An audit of informed consent procedures prior to surgical procedures found that the 
poorest area of information-giving was related to the potential complications of 
various procedures (19). 
The Royal College of Anaesthetists (RCA) has also evaluated patient information 
materials with the specific aim of developing new information resources (20;21). Like 
us, they carried out an in-depth review of patient information with a view to 
developing new, better-quality patient information.  In the process of evaluating the 
leaflets, the RCA also developed an appraisal tool based on the DISCERN tool for 
evaluating patient information, as well as other tools for evaluating health 
information (20).
Although we found that many of the leaflets in our survey did not provide detailed 
information, particularly about the limitations and possible harms of screening, this 
is in line with the findings of a study in which parents’ views were sought about the 
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information they required – parents generally viewed screening as routine, and only 
wanted basic information (22).
It should be noted that the research evidence is in favour of screening either to 
improve health outcomes through early treatment, or to improve parents’ 
experiences of the diagnostic period (3;7;23-25), and that informed choice for 
screening is a relatively new phenomenon.  It is not surprising, therefore, that the 
leaflets are ‘biased’ towards the benefits of screening, and many do not support 
informed choice. With or without informed choice, in an increasingly legalistic 
climate there may be increased pressure to provide patients with detailed 
information to facilitate realistic expectations. The question also arises whether in the 
current climate of informed choice and with increasing patient information available 
some parents may begin to demand more information about screening (19). 
Conclusions and recommendations
We found combining the DISCERN criteria for patient information about treatment 
choices with NSC criteria for implementing screening programmes provided a 
practical route for appraising parent information and identifying examples of clear 
and informative text. We recommend the use of criteria for high quality patient 
information alongside topic or condition-specific guidelines as a starting point for 
developing patient information.
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This survey of leaflets and information sheets illustrates that most health information 
about newborn blood spot screening portrays it in a positive light, and relatively few 
leaflets address difficulties openly.  We therefore conclude that this information 
generally supports the public health agenda of achieving high screening uptake, but 
that exemplar parent information resources facilitate realistic expectations or 
informed choice in newborn screening. 
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Box 1:  Issues addressed when appraising leaflets 
Purpose of Leaflet
Is it clear whom it is for?
If so, how is this indicated in the leaflet?
Is it clear when the information would be given?
Reasons for Screening
Aims/reasons for screening
Description of the conditions screened
Prevention programmes/difficulties of prevention
Process and Consequences of Screening
Description of the heel-prick test
Indication of when parents will receive results
Information on whether screening is not compulsory or mandatory
The limitations of screening (e.g. false-negative, false-positive results)
Costs of screening
Cost-effectiveness of screening
Follow-up to Screening
Information on need for further testing for diagnosis
Treatment for the conditions screened for
Any related services
Information about Carriers
Babies may be identified as carriers
Babies’ DNA may be tested
Mutations tested for
Implications of carrier status for babies’ health
Parents may be identified as carriers
Wider implications for families
Production of the Leaflet
Sources of evidence 
Specific information linked to evidence 
Level of complexity of the leaflet
Indication of how the leaflet was developed
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